RU2019135845A - Анализы для скрининга активности модуляторов членов семейства (17-бета)гидроксистероиддегидрогеназ (hsd17b) - Google Patents
Анализы для скрининга активности модуляторов членов семейства (17-бета)гидроксистероиддегидрогеназ (hsd17b) Download PDFInfo
- Publication number
- RU2019135845A RU2019135845A RU2019135845A RU2019135845A RU2019135845A RU 2019135845 A RU2019135845 A RU 2019135845A RU 2019135845 A RU2019135845 A RU 2019135845A RU 2019135845 A RU2019135845 A RU 2019135845A RU 2019135845 A RU2019135845 A RU 2019135845A
- Authority
- RU
- Russia
- Prior art keywords
- protein
- hsd17b
- substrate
- hsd17b family
- family
- Prior art date
Links
- 108010062875 Hydroxysteroid Dehydrogenases Proteins 0.000 title claims 5
- 102000011145 Hydroxysteroid Dehydrogenases Human genes 0.000 title claims 5
- 238000012216 screening Methods 0.000 title claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 37
- 108090000623 proteins and genes Proteins 0.000 claims 37
- 238000000034 method Methods 0.000 claims 23
- 239000000758 substrate Substances 0.000 claims 22
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 claims 12
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 claims 12
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 claims 12
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- 102100037429 17-beta-hydroxysteroid dehydrogenase 13 Human genes 0.000 claims 4
- 101000806241 Homo sapiens 17-beta-hydroxysteroid dehydrogenase 13 Proteins 0.000 claims 4
- 108060001084 Luciferase Proteins 0.000 claims 4
- 239000005089 Luciferase Substances 0.000 claims 4
- 239000003098 androgen Substances 0.000 claims 4
- 239000005556 hormone Substances 0.000 claims 4
- 229940088597 hormone Drugs 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 229940011871 estrogen Drugs 0.000 claims 3
- 239000000262 estrogen Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 102100037426 17-beta-hydroxysteroid dehydrogenase type 1 Human genes 0.000 claims 2
- 102100022586 17-beta-hydroxysteroid dehydrogenase type 2 Human genes 0.000 claims 2
- 102100039358 3-hydroxyacyl-CoA dehydrogenase type-2 Human genes 0.000 claims 2
- 102100024090 Aldo-keto reductase family 1 member C3 Human genes 0.000 claims 2
- 101000806242 Homo sapiens 17-beta-hydroxysteroid dehydrogenase type 1 Proteins 0.000 claims 2
- 101001045223 Homo sapiens 17-beta-hydroxysteroid dehydrogenase type 2 Proteins 0.000 claims 2
- 101001035740 Homo sapiens 3-hydroxyacyl-CoA dehydrogenase type-2 Proteins 0.000 claims 2
- 101000690306 Homo sapiens Aldo-keto reductase family 1 member C3 Proteins 0.000 claims 2
- 101001045218 Homo sapiens Peroxisomal multifunctional enzyme type 2 Proteins 0.000 claims 2
- 102100022587 Peroxisomal multifunctional enzyme type 2 Human genes 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000000975 bioactive effect Effects 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 150000002066 eicosanoids Chemical class 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 150000002617 leukotrienes Chemical class 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 102100022582 (3R)-3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 claims 1
- 101710120738 (3R)-3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 claims 1
- AKHONHCNYRUTLT-NXBFSHDWSA-N (8R,9S,10R,13S,14S,17S)-15,15,17-trihydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4(O)O)O)[C@@H]4[C@@H]3CCC2=C1 AKHONHCNYRUTLT-NXBFSHDWSA-N 0.000 claims 1
- 102100037425 17-beta-hydroxysteroid dehydrogenase 14 Human genes 0.000 claims 1
- 102100022585 17-beta-hydroxysteroid dehydrogenase type 3 Human genes 0.000 claims 1
- 102100038794 17-beta-hydroxysteroid dehydrogenase type 6 Human genes 0.000 claims 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
- 102100022584 3-keto-steroid reductase/17-beta-hydroxysteroid dehydrogenase 7 Human genes 0.000 claims 1
- CBMYJHIOYJEBSB-YSZCXEEOSA-N 5alpha-androstane-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 CBMYJHIOYJEBSB-YSZCXEEOSA-N 0.000 claims 1
- 102100023400 Estradiol 17-beta-dehydrogenase 11 Human genes 0.000 claims 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims 1
- 101000806245 Homo sapiens 17-beta-hydroxysteroid dehydrogenase 14 Proteins 0.000 claims 1
- 101001045211 Homo sapiens 17-beta-hydroxysteroid dehydrogenase type 3 Proteins 0.000 claims 1
- 101001031333 Homo sapiens 17-beta-hydroxysteroid dehydrogenase type 6 Proteins 0.000 claims 1
- 101001045215 Homo sapiens 3-keto-steroid reductase/17-beta-hydroxysteroid dehydrogenase 7 Proteins 0.000 claims 1
- 101000907855 Homo sapiens Estradiol 17-beta-dehydrogenase 11 Proteins 0.000 claims 1
- 101000742950 Homo sapiens Retinol dehydrogenase 5 Proteins 0.000 claims 1
- 101000806266 Homo sapiens Very-long-chain 3-oxoacyl-CoA reductase Proteins 0.000 claims 1
- 102100038053 Retinol dehydrogenase 5 Human genes 0.000 claims 1
- 102100037438 Very-long-chain 3-oxoacyl-CoA reductase Human genes 0.000 claims 1
- 229960005309 estradiol Drugs 0.000 claims 1
- 229930182833 estradiol Natural products 0.000 claims 1
- 239000003688 hormone derivative Substances 0.000 claims 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 claims 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 claims 1
- 229960003656 ricinoleic acid Drugs 0.000 claims 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003270 steroid hormone Substances 0.000 claims 1
- 229960003604 testosterone Drugs 0.000 claims 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 claims 1
- 229960001670 trilostane Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01239—3Alpha(17beta)-hydroxysteroid dehydrogenase (NAD+) (1.1.1.239), i.e. testosterone 17beta-dehydrogenase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Claims (42)
1. Способ скрининга исследуемого соединения в отношении способности ингибировать белок, являющийся членом семейства (17–бета)гидроксистероиддегидрогеназ (HSD17B), включающий:
a) приведение первого белка, являющегося членом семейства HSD17B, в контакт с исследуемым соединением, субстратом белка, являющегося членом семейства HSD17B, НАД+, предварительно восстановленной формой люциферина, ферментом, который восстанавливает предварительно восстановленную форму люциферина с образованием люциферина, и люциферазой;
b) приведение такого же самого второго белка, являющегося членом семейства HSD17B, в контакт с контролем, субстратом белка, являющегося членом семейства HSD17B, НАД+, предварительно восстановленной формой люциферина, ферментом, который восстанавливает предварительно восстановленную форму люциферина с образованием люциферина, и люциферазой;
c) детекцию длины волны излучения люциферина, образуемого с помощью люциферазы в соответствии со стадией a) и в соответствии со стадией b); и
d) идентификацию исследуемого соединения в качестве ингибитора белка, являющегося членом семейства HSD17B, если излучение длины волны люциферина, образуемого в соответствии со стадией a), ниже, чем длины волны люциферина, образуемого в соответствии со стадией b).
2. Способ по п. 1, отличающийся тем, что белок, являющийся членом семейства HSD17B, представляет собой один или несколько из HSD17B1, HSD17B2, HSD17B3, HSD17B4, HSD17B5, HSD17B6, HSD17B7, HSD17B8, HSD17B9, HSD17B10, HSD17B11, HSD17B12, HSD17B13 или HSD17B14.
3. Способ по п. 1, отличающийся тем, что белок, являющийся членом семейства HSD17B, представляет собой один или несколько из HSD17B1, HSD17B2, HSD17B4, HSD17B5, HSD17B10, HSD17B11 или HSD17B13.
4. Способ по п. 1, отличающийся тем, что белок, являющийся членом семейства HSD17B, представляет собой HSD17B13.
5. Способ по любому из пп. 1–4, отличающийся тем, что субстрат белка, являющегося членом семейства HSD17B, содержит стероидный гормон или его производное.
6. Способ по п. 5, отличающийся тем, что субстрат белка, являющегося членом семейства HSD17B, содержит эстрогеновый гормон.
7. Способ по п. 6, отличающийся тем, что указанный эстрогеновый гормон содержит эстрадиол (E2).
8. Способ по п. 6, отличающийся тем, что указанный эстрогеновый гормон содержит эстрон (E1).
9. Способ по п. 5, отличающийся тем, что субстрат белка, являющегося членом семейства HSD17B, содержит андрогеновый гормон.
10. Способ по п. 9, отличающийся тем, что указанный андрогеновый гормон содержит андростандиол, тестостерон или дигидрокситестостерон (DHT).
11. Способ по п. 5, отличающийся тем, что субстрат белка, являющегося членом семейства HSD17B, содержит производное андрогенового гормона.
12. Способ по п. 11, отличающийся тем, что указанное производное андрогенового гормона содержит трилостан.
13. Способ по любому из пп. 1–4, отличающийся тем, что субстрат белка, являющегося членом семейства HSD17B, содержит жирную кислоту.
14. Способ по п. 13, отличающийся тем, что указанная жирная кислота содержит рицинолевую кислоту.
15. Способ по любому из пп. 1–4, отличающийся тем, что субстрат белка, являющегося членом семейства HSD17B, содержит биоактивный липид.
16. Способ по п. 15, отличающийся тем, что указанный биоактивный липид содержит эйкозаноид.
17. Способ по п. 16, отличающийся тем, что эйкозаноид содержит лейкотриен.
18. Способ по п. 17, отличающийся тем, что указанный лейкотриен содержит лейкотриен В4.
19. Способ по п. 4, отличающийся тем, что первый и второй белок, являющийся членом семейства HSD17B, представляет собой белок HSD17B13, который содержит аминокислотную последовательность, которая на, по меньшей мере, приблизительно 90% идентична SEQ ID NO:1.
20. Способ по п. 19, отличающийся тем, что первый и второй белок HSD17B13 содержит аминокислотную последовательность SEQ ID NO:1.
21. Набор, содержащий:
белок, являющийся членом семейства a (17–бета)гидроксистероиддегидрогеназ (HSD17B), или клетку, экспрессирующую белок, являющийся членом семейства HSD17B;
субстрат белка, являющегося членом семейства HSD17B; и
инструкции для применения белка, являющегося членом семейства HSD17B, и его субстрата в способе скрининга исследуемого соединения в отношении способности ингибировать белок, являющийся членом семейства HSD17B.
22. Набор по п. 21, отличающийся тем, что указанный набор дополнительно содержит НАД+, предварительно восстановленную форму люциферина, фермент, который восстанавливает предварительно восстановленную форму люциферина с образованием люциферина, и люциферазу.
23. Способ скрининга исследуемого соединения в отношении способности ингибировать белок, являющийся членом семейства (17–бета)гидроксистероиддегидрогеназ (HSD17B), включающий:
a) приведение первой клетки, экспрессирующей белок, являющийся членом семейства HSD17B, в контакт с исследуемым соединением и субстратом белка, являющегося членом семейства HSD17B;
b) приведение второй клетки, экспрессирующей такой же белок, являющийся членом семейства HSD17B, в контакт с контролем и субстратом белка, являющегося членом семейства HSD17B;
c) определение уровня расхода субстрата клеткой в соответствии со стадией a) и в соответствии со стадией b); и
d) идентификацию исследуемого соединения в качестве ингибитора белка, являющегося членом семейства HSD17B, если уровень расхода субстрата в соответствии со стадией a) ниже, чем уровень расхода субстрата, образуемого в соответствии со стадией b).
24. Способ скрининга исследуемого соединения в отношении способности ингибировать белок, являющийся членом семейства (17–бета)гидроксистероиддегидрогеназ (HSD17B), включающий:
a) приведение первой клетки, экспрессирующей белок, являющийся членом семейства HSD17B, в контакт с исследуемым соединением и субстратом белка, являющегося членом семейства HSD17B;
b) приведение второй клетки, экспрессирующей такой же белок, являющийся членом семейства HSD17B, в контакт с контролем и субстратом белка, являющегося членом семейства HSD17B;
c) определение уровня продукта субстрата, образуемого клеткой в соответствии со стадией a) и в соответствии со стадией b); и
d) идентификацию исследуемого соединения в качестве ингибитора белка, являющегося членом семейства HSD17B, если уровень продукта субстрата, образуемого в соответствии со стадией a), ниже, чем уровень продукта субстрата, образуемого в соответствии со стадией b).
25. Комплекс, содержащий белок, являющийся членом семейства HSD17B, и субстрат белка, являющегося членом семейства HSD17B.
26. Комплекс по п. 25, присутствующий в композиции, содержащей носитель.
27. Композиция, содержащая белок, являющийся членом семейства HSD17B, субстрат белка, являющегося членом семейства HSD17B, и носитель.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762484141P | 2017-04-11 | 2017-04-11 | |
| US62/484,141 | 2017-04-11 | ||
| PCT/US2018/021109 WO2018190970A1 (en) | 2017-04-11 | 2018-03-06 | Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2019135845A true RU2019135845A (ru) | 2021-05-11 |
Family
ID=61911665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019135845A RU2019135845A (ru) | 2017-04-11 | 2018-03-06 | Анализы для скрининга активности модуляторов членов семейства (17-бета)гидроксистероиддегидрогеназ (hsd17b) |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11479802B2 (ru) |
| EP (1) | EP3610029A1 (ru) |
| JP (1) | JP2020516283A (ru) |
| KR (1) | KR20190139869A (ru) |
| CN (1) | CN110325649A (ru) |
| AU (1) | AU2018250727A1 (ru) |
| CA (1) | CA3059348A1 (ru) |
| IL (1) | IL269790A (ru) |
| MX (1) | MX2019012169A (ru) |
| RU (1) | RU2019135845A (ru) |
| SG (1) | SG11201909453RA (ru) |
| WO (1) | WO2018190970A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8259121B2 (en) | 2002-10-22 | 2012-09-04 | Broadcom Corporation | System and method for processing data using a network |
| WO2021211981A1 (en) * | 2020-04-18 | 2021-10-21 | Inipharm, Inc. | Substrate selective hsd17b13 inhibitors and uses thereof |
| WO2022098757A1 (en) * | 2020-11-06 | 2022-05-12 | Inipharm, Inc. | Specific substrates and products of hsd17b13 as markers of liver disease and biomarkers for liver disease treatment |
| CN116602243A (zh) * | 2023-05-12 | 2023-08-18 | 中国科学院海洋研究所 | 一种牙鲆17β-羟类固醇脱氢酶12b的应用 |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5624813A (en) * | 1994-04-21 | 1997-04-29 | Mahant; Vijay K. | NAD(P)+ /NAD(P)H based chemiluminescent diagnostics |
| FR2739029B1 (fr) * | 1995-09-21 | 1997-11-21 | Roussel Uclaf | Nouvelle application therapeutique des composes antimineralo-corticoides |
| AU1067697A (en) | 1995-12-05 | 1997-06-27 | Jouko Antero Oikarinen | Hsd17b1 promoter, enhancer, silencer and use thereof |
| US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
| RU2000125533A (ru) | 1998-03-11 | 2002-10-20 | Эндорешерш, Инк. (Ca) | Ингибиторы 17-бета-гидроксистероиддегидрогеназ 5 и 3 типа и способы их применения |
| FR2801218B1 (fr) * | 1999-11-23 | 2001-12-28 | Hoechst Marion Roussel Inc | Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant |
| US7754709B2 (en) | 2003-06-10 | 2010-07-13 | Solvay Pharmaceuticals Bv | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds |
| US20090169585A1 (en) | 2003-10-23 | 2009-07-02 | Resveratrol Partners, Llc | Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity |
| US20050158376A1 (en) | 2003-10-23 | 2005-07-21 | Sardi William F. | Dietary supplement and method of processing same |
| WO2005108415A2 (en) | 2004-04-30 | 2005-11-17 | Biogen Idec Ma Inc. | Membrane associated molecules |
| CA2852855C (en) | 2004-05-07 | 2016-07-05 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof |
| FR2904000A1 (fr) * | 2006-07-19 | 2008-01-25 | Galderma Res & Dev S N C Snc | Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee |
| US7951776B2 (en) | 2006-09-01 | 2011-05-31 | American Type Culture Collection | Methods for treatment of type 1 diabetes |
| US20090203602A1 (en) | 2006-09-01 | 2009-08-13 | Cohava Gelber | Compositions and methods for diagnosis and treatment of type 2 diabetes |
| US20080300170A1 (en) | 2006-09-01 | 2008-12-04 | Cohava Gelber | Compositions and methods for diagnosis and treatment for type 2 diabetes |
| US20100267052A1 (en) | 2006-09-01 | 2010-10-21 | American Type Culture Collection | Compositions and methods for diagnosis and treatment of type 2 diabetes |
| WO2008091873A2 (en) | 2007-01-24 | 2008-07-31 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the identification, assessment, prevention and therapy of thymic lymphoma or hamartomatous tumours |
| CA2699908C (en) | 2007-09-20 | 2012-09-11 | Resveratrol Partners, Llc | Resveratrol-containing compositions for modulating gene product concentration or activity |
| WO2009148137A1 (ja) | 2008-06-04 | 2009-12-10 | 協和発酵キリン株式会社 | 肥満細胞の脱顆粒を制御する核酸 |
| US20100056384A1 (en) | 2008-09-04 | 2010-03-04 | Board Of Regents, The University Of Texas System | Sequence Variations in PNPLA3 Associated with Hepatic Steatosis |
| US20100209427A1 (en) | 2008-09-24 | 2010-08-19 | Yu Li | Lysine acetylation sites |
| EP2177615A1 (en) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
| JPWO2010064702A1 (ja) | 2008-12-05 | 2012-05-10 | 国立大学法人 東京大学 | 癌の予後を予測するためのバイオマーカー |
| US20100266618A1 (en) | 2009-03-18 | 2010-10-21 | Children's Hospital Of Eastern Ontario Research Institute | Compositions and methods for augmenting activity of oncolytic viruses |
| WO2010120526A2 (en) | 2009-03-31 | 2010-10-21 | Emory University | Methods and systems for screening for and diagnosing dna methylation associated with autism spectrum disorders |
| WO2010147992A1 (en) | 2009-06-15 | 2010-12-23 | Alnylam Pharmaceuticals, Inc. | Methods for increasing efficacy of lipid formulated sirna |
| WO2011008348A2 (en) | 2009-07-15 | 2011-01-20 | Calimmune Inc. | Dual vector for inhibition of human immunodeficiency virus |
| WO2011006214A1 (en) | 2009-07-16 | 2011-01-20 | Peter Maccallum Cancer Institute | Method of detecting radiation exposure and adverse toxicity thereto |
| WO2011066458A2 (en) | 2009-11-25 | 2011-06-03 | Prometheus Laboratories Inc. | Novel genomic biomarkers for irritable bowel syndrome diagnosis |
| WO2011084747A2 (en) | 2009-12-21 | 2011-07-14 | The Johns Hopkins University | Compositions and methods for somatic tissue induced pluripotent stem cells having an endoderm origin |
| WO2011127561A1 (en) | 2010-04-12 | 2011-10-20 | University Health Network | Methods and compositions for diagnosing pulmonary fibrosis subtypes and assessing the risk of primary graft dysfunction after lung transplantation |
| WO2011128096A1 (en) | 2010-04-16 | 2011-10-20 | Roche Diagnostics Gmbh | Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment |
| US20130237454A1 (en) | 2010-05-12 | 2013-09-12 | Steven E. Schutzer | Diagnostic markers for neuropsychiatric disease |
| US8945847B2 (en) | 2010-05-24 | 2015-02-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for ascertaining biosafety of an agent |
| US20120058088A1 (en) | 2010-06-28 | 2012-03-08 | Resveratrol Partners, Llc | Resveratrol-Containing Compositions And Methods Of Use |
| CA2804763C (en) | 2010-07-14 | 2023-01-03 | The Regents Of The University Of California | Biomarkers for diagnosis of transient ischemic attacks |
| WO2012031008A2 (en) | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| WO2012052953A1 (en) | 2010-10-20 | 2012-04-26 | Fondazione Centro San Raffaele Del Monte Tabor | MiRNA |
| RU2603731C2 (ru) | 2010-10-26 | 2016-11-27 | Бак Инститьют Фор Эйдж Рисёрч | Понижающая регуляция трансктипции sine/alu ретротранспозонов для индукции или восстановления способности к пролиферации и/или плюрипотентности стволовой клетки |
| WO2012087983A1 (en) | 2010-12-20 | 2012-06-28 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| ES2633565T3 (es) | 2010-11-12 | 2017-09-22 | The General Hospital Corporation | ARN no codificantes asociados a polycomb |
| US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| WO2012070014A2 (en) | 2010-11-26 | 2012-05-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Identification of novel cell surface markers for pancreatic progenitor cells and definite endodermal cells |
| WO2012080816A2 (en) | 2010-12-16 | 2012-06-21 | Norwegian University Of Science And Technology (Ntnu) | Single nucleotide polymorphism associated with risk of insulin resistance development |
| EP2704728A4 (en) | 2011-05-03 | 2015-04-22 | Dermachip Inc | EXPRESSION SIGNATURES OF AGENTS ASSOCIATED WITH SKIN AGING AND GEN NETWORKS |
| GB201112246D0 (en) | 2011-07-15 | 2011-08-31 | Univ Birmingham | Diagnosis of alzheimer's disease |
| US20130079241A1 (en) | 2011-09-15 | 2013-03-28 | Jianhua Luo | Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse |
| WO2013126565A1 (en) | 2012-02-24 | 2013-08-29 | Lunyak Victoria V | Downregulation of sine/alu retrotransposon transcription to induce or restore proliferative capacity and/or pluripotency to a stem cell |
| WO2013166264A2 (en) | 2012-05-02 | 2013-11-07 | University Of Georgia Research Foundation, Inc. | Methods for altering virus replication |
| US9677138B2 (en) | 2012-05-20 | 2017-06-13 | Trustees Of Boston University | Methods and systems for monitoring, diagnosing, and treating chronic obstructive pulmonary disease |
| LT4289948T (lt) | 2012-05-25 | 2025-05-12 | The Regents Of The University Of California | Į rnr nukreipto tikslinio dnr modifikavimo ir į rnr nukreipto transkripcijos moduliavimo metodai ir kompozicijos |
| US20150147761A1 (en) | 2012-06-20 | 2015-05-28 | Helmut E. Meyer | Specific biomarkers for hepatocellular carcinoma (hcc) |
| US20140004153A1 (en) | 2012-07-02 | 2014-01-02 | Lancell, L.L.C. | Use of somatic mutations in the extracellular domain of transmembrane proteins in a patient's tumor as immunogens for active humoral immunotherapy of cancer |
| US9526720B2 (en) | 2012-08-17 | 2016-12-27 | The Broad Institute, Inc. | Modulators of hepatic lipoprotein metabolism |
| PL2900270T3 (pl) | 2012-09-26 | 2019-09-30 | Tangent Reprofiling Limited | Połączenie benzo(izo)oksazolopiperydyn ze sprzężonym kwasem linolowym |
| US9375433B2 (en) | 2012-09-26 | 2016-06-28 | Tangent Reprofiling Limited | Modulators of androgen synthesis |
| BR112015013105B1 (pt) | 2012-12-05 | 2022-02-08 | Alnylam Pharmaceuticals, Inc | Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro |
| EP4331620A3 (en) | 2012-12-07 | 2024-12-04 | Translate Bio, Inc. | Lipidic nanoparticles for mrna delivery |
| ES2692363T3 (es) | 2013-03-14 | 2018-12-03 | Translate Bio, Inc. | Composiciones terapéuticas de ARNm y su uso para tratar enfermedades y trastornos |
| US20160032395A1 (en) | 2013-03-14 | 2016-02-04 | Elai Davicioni | Cancer biomarkers and classifiers and uses thereof |
| EP2971128B1 (en) | 2013-03-15 | 2023-03-01 | Veracyte, Inc. | Biomarkers for diagnosis of lung diseases and methods of use thereof |
| US20140329704A1 (en) | 2013-03-28 | 2014-11-06 | President And Fellows Of Harvard College | Markers for mature beta-cells and methods of using the same |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| ES2677915T3 (es) | 2013-06-03 | 2018-08-07 | Nestec S.A. | Método para diagnosticar valvulopatías crónicas |
| US9574241B2 (en) | 2013-06-03 | 2017-02-21 | The Trustees Of Columbia University In The City Of New York | Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T-cell lymphomas |
| CN113425857B (zh) | 2013-06-17 | 2025-05-16 | 布罗德研究所有限公司 | 用于肝靶向和治疗的crispr-cas系统、载体和组合物的递送与用途 |
| SG11201510327TA (en) | 2013-06-17 | 2016-01-28 | Broad Inst Inc | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells |
| US20150079062A1 (en) | 2013-07-12 | 2015-03-19 | Patrick J. Casey | Method for harvesting, processing, and storage of proteins from the mammalian feto-placental unit and use of such proteins in compositions and medical treatment |
| US20150079061A1 (en) | 2013-07-12 | 2015-03-19 | Patrick J. Casey | Method for the harvesting, processing, and storage of proteins from the mammalian feto-placental unit and use of such proteins in compositions and medical treatment |
| RU2545990C2 (ru) | 2013-07-16 | 2015-04-10 | Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы | Способ дифференциальной диагностики стеатоза печени и стеатогепатита |
| BR112016009077A2 (pt) | 2013-10-22 | 2017-09-19 | Shire Human Genetic Therapies | Formulações lipídicas para fornecimento de rna mensageiro |
| CN103520724B (zh) | 2013-10-23 | 2016-05-25 | 江苏美迪森生物医药有限公司 | Hsd17b13蛋白或其编码基因的抑制剂的新用途 |
| GB201320061D0 (en) | 2013-11-13 | 2013-12-25 | Electrophoretics Ltd | Materials nad methods for diagnosis and prognosis of liver cancer |
| WO2015169971A1 (en) | 2014-05-09 | 2015-11-12 | Tangent Reprofiling Limited | Modulators of androgen synthesis |
| EP3155116A4 (en) | 2014-06-10 | 2017-12-27 | Massachusetts Institute Of Technology | Method for gene editing |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| WO2016004387A1 (en) | 2014-07-02 | 2016-01-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Gene expression signature for cancer prognosis |
| EP3169339A1 (en) | 2014-07-14 | 2017-05-24 | Patrick J. Casey | Method for the harvesting, processing, and storage of proteins from the mammalian feto-placental unit and use of such proteins in compositions and medical treatment |
| WO2016028638A1 (en) | 2014-08-18 | 2016-02-25 | Drexel University | Methods, computer-readable media, and systems for assessing samples and wounds, predicting whether a wound will heal, and monitoring effectiveness of a treatment |
| CN114606309A (zh) | 2014-11-05 | 2022-06-10 | 威拉赛特公司 | 使用机器学习和高维转录数据的诊断系统和方法 |
| WO2016130806A2 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| CN104698108B (zh) * | 2015-03-26 | 2016-11-09 | 中国药科大学 | 一种利用固定化酶筛选I型17β羟类固醇脱氢酶抑制剂的方法 |
| EP3350328A1 (en) | 2015-09-14 | 2018-07-25 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
| EP3159407A1 (en) | 2015-10-23 | 2017-04-26 | Silence Therapeutics (London) Ltd | Guide rnas, methods and uses |
| WO2017100542A1 (en) | 2015-12-10 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof |
| CA3005249A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Compositions and methods for treatment of kidney diseases |
| CA3005128A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Compositions and methods for treatment of eye diseases |
| CA3005090A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Compositions and methods for treatment of liver diseases |
| WO2017106375A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of tuberous sclerosis complex |
| EP3390642B1 (en) | 2015-12-14 | 2021-11-24 | Cold Spring Harbor Laboratory | Compositions for treatment of retinitis pigmentosa 13 |
| WO2017106210A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of alagille syndrome |
| EP4104867A3 (en) | 2015-12-14 | 2023-03-01 | Cold Spring Harbor Laboratory | Compositions and methods for treatment of central nervous system diseases |
| CN109790643A (zh) | 2016-03-09 | 2019-05-21 | 分子听诊器公司 | 用于检测组织状况的方法和系统 |
| IL304057B2 (en) | 2016-03-16 | 2025-03-01 | Spogen Biotech Inc | Methods for promoting plant health using free enzymes and microorganisms that cause enzyme overexpression |
| US11078247B2 (en) | 2016-05-04 | 2021-08-03 | Curevac Ag | RNA encoding a therapeutic protein |
| US10036024B2 (en) | 2016-06-03 | 2018-07-31 | Purdue Research Foundation | siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD) |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| GB201609977D0 (en) | 2016-06-08 | 2016-07-20 | Cancer Rec Tech Ltd | Chemosensitivity predictive biomarkers |
| CA3046376A1 (en) | 2016-12-08 | 2018-06-14 | Intellia Therapeutics, Inc. | Modified guide rnas |
| WO2018107026A1 (en) | 2016-12-09 | 2018-06-14 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
| RU2019121992A (ru) | 2016-12-14 | 2021-01-15 | Лигандал, Инк. | Способы и композиции для доставки полезной нагрузки в виде нуклеиновых кислот и белков |
| CN110199032A (zh) | 2017-01-23 | 2019-09-03 | 雷杰纳荣制药公司 | 羟基类固醇17-β脱氢酶13(HSD17B13)变体及其用途 |
| CN118581154A (zh) | 2017-06-02 | 2024-09-03 | 国家健康与医学研究院 | 用于遗传障碍的基因疗法的基因组编辑手段和结合病毒载体的基因疗法 |
| AU2019239971A1 (en) | 2018-03-21 | 2020-09-03 | Regeneron Pharmaceuticals, Inc. | 17beta-hydroxysteroid dehydrogenase type 13 (HSD17b13) iRNA compositions and methods of use thereof |
| US20210000906A1 (en) | 2018-03-21 | 2021-01-07 | Ionis Pharmaceuticals, Inc. | Modulation of hsd17b13 expression |
| US11690921B2 (en) | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
| BR112020024731A2 (pt) | 2018-06-08 | 2021-03-23 | Intellia Therapeutics, Inc. | rnas guias modificados para edição de gene |
| GB2596224B (en) | 2018-06-19 | 2022-09-07 | Univ Texas | Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids |
-
2018
- 2018-03-06 EP EP18716391.0A patent/EP3610029A1/en not_active Withdrawn
- 2018-03-06 CA CA3059348A patent/CA3059348A1/en not_active Abandoned
- 2018-03-06 US US15/913,366 patent/US11479802B2/en active Active
- 2018-03-06 RU RU2019135845A patent/RU2019135845A/ru not_active Application Discontinuation
- 2018-03-06 JP JP2019555694A patent/JP2020516283A/ja active Pending
- 2018-03-06 KR KR1020197029994A patent/KR20190139869A/ko not_active Withdrawn
- 2018-03-06 SG SG11201909453R patent/SG11201909453RA/en unknown
- 2018-03-06 MX MX2019012169A patent/MX2019012169A/es unknown
- 2018-03-06 WO PCT/US2018/021109 patent/WO2018190970A1/en unknown
- 2018-03-06 AU AU2018250727A patent/AU2018250727A1/en not_active Abandoned
- 2018-03-06 CN CN201880013512.8A patent/CN110325649A/zh active Pending
-
2019
- 2019-10-03 IL IL26979019A patent/IL269790A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11479802B2 (en) | 2022-10-25 |
| CN110325649A (zh) | 2019-10-11 |
| CA3059348A1 (en) | 2018-10-18 |
| EP3610029A1 (en) | 2020-02-19 |
| JP2020516283A (ja) | 2020-06-11 |
| AU2018250727A1 (en) | 2019-10-31 |
| SG11201909453RA (en) | 2019-11-28 |
| IL269790A (en) | 2019-11-28 |
| MX2019012169A (es) | 2019-12-11 |
| WO2018190970A1 (en) | 2018-10-18 |
| KR20190139869A (ko) | 2019-12-18 |
| US20180291422A1 (en) | 2018-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019135845A (ru) | Анализы для скрининга активности модуляторов членов семейства (17-бета)гидроксистероиддегидрогеназ (hsd17b) | |
| Ge et al. | Developmental changes in glucocorticoid receptor and 11β-hydroxysteroid dehydrogenase oxidative and reductive activities in rat Leydig cells | |
| Iwanari et al. | Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences | |
| MacLusky et al. | Aromatase in the cerebral cortex, hippocampus, and mid-brain: ontogeny and developmental implications | |
| Gozgit et al. | Differential action of polycyclic aromatic hydrocarbons on endogenous estrogen-responsive genes and on a transfected estrogen-responsive reporter in MCF-7 cells | |
| Asada et al. | 5α-reductase type 2 is constitutively expressed in the dermal papilla and connective tissue sheath of the hair follicle in vivo but not during culture in vitro | |
| Vinggaard et al. | Antiandrogenic effects in short-term in vivo studies of the fungicide fenarimol | |
| Santillo et al. | d-aspartate affects NMDA receptor-extracellular signal–regulated kinase pathway and upregulates androgen receptor expression in the rat testis | |
| Ruenwai et al. | Heterologous production of polyunsaturated fatty acids in Saccharomyces cerevisiae causes a global transcriptional response resulting in reduced proteasomal activity and increased oxidative stress | |
| Gak et al. | Stress triggers mitochondrial biogenesis to preserve steroidogenesis in Leydig cells | |
| Li et al. | The orphan nuclear receptor NR4A1 regulates transcription of key steroidogenic enzymes in ovarian theca cells | |
| Ooi et al. | Relationship between testosterone, estradiol and circulating PCSK9: Cross-sectional and interventional studies in humans | |
| Leskelä et al. | Estrogen receptor alpha genotype confers interindividual variability of response to estrogen and testosterone in mesenchymal-stem-cell-derived osteoblasts | |
| Yamagata et al. | Docosahexaenoic acid prevented tumor necrosis factor alpha-induced endothelial dysfunction and senescence | |
| Gray et al. | Effects of nuclear receptor transactivation on steroid hormone synthesis and gene expression in porcine Leydig cells | |
| Zhao et al. | Inhibition of 3β-and 17β-hydroxysteroid dehydrogenase activities in rat Leydig cells by perfluorooctane acid | |
| Landreh et al. | Phenotype and steroidogenic potential of PDGFRα-positive rat neonatal peritubular cells | |
| Wang et al. | Cystathionine gamma-lyase expression is regulated by exogenous hydrogen peroxide in the mammalian cells | |
| Krivoruchko et al. | Molecular mechanisms of turtle anoxia tolerance: A role for NF-κB | |
| Del Bufalo et al. | Contact sensitizers modulate the arachidonic acid metabolism of PMA-differentiated U-937 monocytic cells activated by LPS | |
| Nomoto et al. | Bile acid-induced elevated oxidative stress in the absence of farnesoid X receptor | |
| Quillfeldt et al. | Measuring corticosterone in seabird egg yolk and the presence of high yolk gestagen concentrations | |
| Zimmer et al. | Sulfation pathways: Expression of SULT2A1, SULT2B1 and HSD3B1 in the porcine testis and epididymis | |
| Rao et al. | Thioredoxin and thioredoxin reductase influence estrogen receptor α-mediated gene expression in human breast cancer cells | |
| Mak et al. | A yeast screen system for aromatase inhibitors and ligands for androgen receptor: yeast cells transformed with aromatase and androgen receptor. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20210309 |